热门资讯> 正文

External Safety Review Committee Recommended Pasithea Therapeutics' Phase 1/1b Study To Assess PAS-004 For Neurofibromatosis Type 1 To Proceed To Cohort 2, 8mg Tablet, Without Modification, Initial Interim Data From First Two Cohorts Expected In Q1 2026

2025-09-08 19:08

亚玛芬体育(AS) 0

Recommendation that trial escalate to next dose level of 8mg tablet --
Initial interim clinical data from first two cohorts expected in Q1 2026

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。